Homeostasis of iron and hepcidin in erythropoietic protoporphyria

European Journal of Clinical Investigation

Volumn 45, Issue 10, 2015, Pages 1032-1041

  Bossi, Krista ^a   Lee, Jingyun ^a   Schmeltzer, Paul ^a   Holburton, Eric ^a   Groseclose, Gale ^a   Besur, Siddesh ^a   Hwang, Sunil ^a   Bonkovsky, Herbert L ^a,b  

^a LEVINE CANCER INSTITUTE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Anaemia; Erythropoietic protoporphyria; Erythropoietin; Hepcidin; Iron; Protoporphyrin

Indexed keywords

CREATININE; ERYTHROPOIETIN; FERRITIN; FERROUS SULFATE; HEMOGLOBIN; HEPCIDIN; IRON; CYTOKINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ERYTHROPOIETIC PROTOPORPHYRIA; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS; HUMAN; INTESTINE ABSORPTION; IRON ABSORPTION; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON HOMEOSTASIS; IRON URINE LEVEL; MALE; MUTATION; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN HOMEOSTASIS; URINALYSIS; X LINKED PROTOPORPHYRIA; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; CASE-CONTROL STUDIES; CYTOKINES; ERYTHROPOIETIN; FERRITINS; HEPCIDINS; HOMEOSTASIS; HUMANS; IRON; MALE; MIDDLE AGED; PROTOPORPHYRIA, ERYTHROPOIETIC;

EID: 84941993014     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12503     Document Type: Article

References (27)

1. Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic & Molecular Bases of Inherited Disease. 8th edn. New York: McGraw-Hill Medical Publishing Division; 2001: pp 2991-3062.
2. Bonkovsky HL, Guo JT, Hou W, Li T, Narang T, Thapar M. Porphyrin and heme metabolism and the porphyrias. Compr Physiol 2013;3:365-401.
3. Balwani M, Doheny D, Bishop DF, Nazarenko I, Yasuda M, Dailey HA et al. Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria. Mol Med 2013;19:26-35.
4. Katugampola RP, Badminton MN, Finlay AY, Whatley S, Woolf J, Mason N et al. Congenital erythropoietic porphyria: a single-observer clinical study of 29 cases. Br J Dermatol 2012;167:901-13.
5. Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005;142:439-50.
6. McGuire BM, Bonkovsky HL, Carithers RL Jr, Chung RT, Goldstein LI, Lake JR et al. Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl 2005;11:1590-6.
7. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, Di Bisceglie A, Tattrie C et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998;27:1661-9.
8. Bloomer JR, Bonkovsky HL. The porphyrias. Dis Mon 1989;35:1-54.
9. Schrier SL. Causes and Diagnosis of Iron Deficiency Anemia in the Adult. Available at: http://www.uptodate.com/contents/causes-and-diagnosis-of-iron-deficiency-anemia-in-the-adult?source=search_result&search=causes+and+diagnosis+iron+deficiency+anemia&selectedTitle=1~150. Accessed on 23 July 2015.
10. Holme SA, Worwood M, Anstey AV, Elder GH, Badminton MN. Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. Blood 2007;110:4108-10.
11. Shah DI, Takahashi-Makise N, Cooney JD, Li L, Schultz IJ, Pierce EL et al. Mitochondrial Atpif1 regulates haem synthesis in developing erythroblasts. Nature 2012;491:608-12.
12. Holme SA, Thomas CL, Whatley SD, Bentley DP, Anstey AV, Badminton MN. Symptomatic response of erythropoietic protoporphyria to iron supplementation. J Am Acad Dermatol 2007;56:1070-2.
13. Bentley DP, Meek EM. Clinical and biochemical improvement following low-dose intravenous iron therapy in a patient with erythropoietic protoporphyria. Br J Haematol 2013;163:289-91.
14. Minder EI, Haldemann AR, Schneider-Yin X. Exacerbation of erythropoietic protoporphyria by hyperthyroidism. J Inherit Metab Dis 2010;33(Suppl 3):S465-9.
15. Milligan A, Graham-Brown RA, Sarkany I, Baker H. Erythropoietic protoporphyria exacerbated by oral iron therapy. Br J Dermatol 1988;119:63-6.
16. Barman-Aksozen J, Minder EI, Schubiger C, Biolcati G, Schneider-Yin X. In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentration correlates with iron availability. Blood Cells Mol Dis 2015;54:71-7.
17. Mathews-Roth MM. Letter: Anemia in erythropoietic protoporphyria. JAMA 1974;230:824.
18. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med 2011;62:347-60.
19. Muckenthaler MU. Fine tuning of hepcidin expression by positive and negative regulators. Cell Metab 2008;8:1-3.
20. Zhao N, Zhang AS, Enns CA. Iron regulation by hepcidin. J Clin Invest 2013;123:2337-43.
21. Bossi K, Lee J, Schmeltzer P, Holburton E, Groseclose G, Besur S et al. Homeostasis of iron and hepcidin in erythropoietic protoporphyria and X-Linked protoporphyria. Annual Meeting American College of Gastroenterology; Oct. 17-22; Philadephia, PA2014.
22. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
23. Hwang SI, Lee YY, Park JO, Norton HJ, Clemens E, Schrum LW et al. Effects of a single dose of oral iron on hepcidin concentrations in human urine and serum analyzed by a robust LC-MS/MS method. Clin Chim Acta 2011;412:2241-7.
24. Ruchala P, Nemeth E. The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci 2014;35:155-61.
25. Lyoumi S, Abitbol M, Andrieu V, Henin D, Robert E, Schmitt C et al. Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice. Blood 2007;109:811-8.
26. Delaby C, Lyoumi S, Ducamp S, Martin-Schmitt C, Gouya L, Deybach JC et al. Excessive erythrocyte PPIX influences the hematologic status and iron metabolism in patients with dominant erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand) 2009;55:45-52.
27. Wang Y, Langer NB, Shaw GC, Yang G, Li L, Kaplan J et al. Abnormal mitoferrin-1 expression in patients with erythropoietic protoporphyria. Exp Hematol 2011;39:784-94.